John G. Bennetts
Director/Board Member at MCMILLAN SHAKESPEARE LIMITED
Net worth: 39 M $ as of 30/03/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ronald George Pitcher | M | 84 |
Cellestis Pty Ltd.
Cellestis Pty Ltd. BiotechnologyHealth Technology Cellestis Ltd. develops, manufactures and markets medical diagnostic products. It develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. Its product portfolio includes QuantiFERON-CMI kit, an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood, QuantiFERON-TB Gold, an in vitro diagnostic test for the detection of mycobacterium tuberculosis infection. The company was founded in 2000 and is headquartered in Chadstone, Australia. | 23 years |
Teodor Stelmasiak | M | - |
Glutagen Pty Ltd.
Glutagen Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Glutagen Pty Ltd. develops enzyme therapies for the treatment of gluten intolerance and coeliac disease. The company has two products Glutazyme and Glutaren. The company was founded by Teodor Stelmasiak in 2001 and is headquartered in South Melbourne, Australia. | 23 years |
Helen Kurincic | F | - | 6 years | |
Bruce Akhurst | M | 64 | 3 years | |
James Stuart Rothel | M | - |
Cellestis Pty Ltd.
Cellestis Pty Ltd. BiotechnologyHealth Technology Cellestis Ltd. develops, manufactures and markets medical diagnostic products. It develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. Its product portfolio includes QuantiFERON-CMI kit, an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood, QuantiFERON-TB Gold, an in vitro diagnostic test for the detection of mycobacterium tuberculosis infection. The company was founded in 2000 and is headquartered in Chadstone, Australia. | 24 years |
Roland Sackers | M | 56 |
Cellestis Pty Ltd.
Cellestis Pty Ltd. BiotechnologyHealth Technology Cellestis Ltd. develops, manufactures and markets medical diagnostic products. It develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. Its product portfolio includes QuantiFERON-CMI kit, an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood, QuantiFERON-TB Gold, an in vitro diagnostic test for the detection of mycobacterium tuberculosis infection. The company was founded in 2000 and is headquartered in Chadstone, Australia. | - |
Ashley Conn | M | 49 | 4 years | |
Kathryn Parsons | F | - | 4 years | |
Arlene Tansey | F | 66 | 2 years | |
Robert de Luca | M | - | 2 years | |
Anthony Vella | M | - | 1 years | |
Yeung Wai Yim | M | 60 | 3 years | |
Peer Schatz | M | 57 |
Cellestis Pty Ltd.
Cellestis Pty Ltd. BiotechnologyHealth Technology Cellestis Ltd. develops, manufactures and markets medical diagnostic products. It develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. Its product portfolio includes QuantiFERON-CMI kit, an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood, QuantiFERON-TB Gold, an in vitro diagnostic test for the detection of mycobacterium tuberculosis infection. The company was founded in 2000 and is headquartered in Chadstone, Australia. | - |
Rohan Martin | M | - | 12 years | |
Wayne Fitzsimmons | M | - |
Mooroolbark Investments Pty Ltd.
Mooroolbark Investments Pty Ltd. Investment ManagersFinance Mooroolbark Investments Pty Ltd (M-Group) is the venture capital arm of Mooroolbark Group founded in 1997. The firm is headquartered in Victoria, Australia. | - |
Ronald Cattell | M | - |
Mooroolbark Investments Pty Ltd.
Mooroolbark Investments Pty Ltd. Investment ManagersFinance Mooroolbark Investments Pty Ltd (M-Group) is the venture capital arm of Mooroolbark Group founded in 1997. The firm is headquartered in Victoria, Australia. | 20 years |
Antonino Catanzaro | M | - |
Cellestis Pty Ltd.
Cellestis Pty Ltd. BiotechnologyHealth Technology Cellestis Ltd. develops, manufactures and markets medical diagnostic products. It develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. Its product portfolio includes QuantiFERON-CMI kit, an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood, QuantiFERON-TB Gold, an in vitro diagnostic test for the detection of mycobacterium tuberculosis infection. The company was founded in 2000 and is headquartered in Chadstone, Australia. | 23 years |
Ross Chessari | M | 62 | 21 years | |
Helene Gordon | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul McCluskey | M | - | 5 years | |
Anthony Radford | M | - |
Cellestis Pty Ltd.
Cellestis Pty Ltd. BiotechnologyHealth Technology Cellestis Ltd. develops, manufactures and markets medical diagnostic products. It develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. Its product portfolio includes QuantiFERON-CMI kit, an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood, QuantiFERON-TB Gold, an in vitro diagnostic test for the detection of mycobacterium tuberculosis infection. The company was founded in 2000 and is headquartered in Chadstone, Australia. | 12 years |
Timothy Poole | M | 55 | 9 years | |
Michael Salisbury | M | 59 | 14 years | |
Ian Elliot | M | 69 | 7 years | |
Michael Kay | M | 66 | 6 years | |
Mark Cansdale | M | - | 2 years | |
Graeme John McMahon | M | 84 | 9 years | |
Peter Lang | M | - | 14 years | |
Anthony G. Podesta | M | 68 | 26 years | |
Susanne Dahn | F | - | 2 years | |
Brian H. Manuel | M | - |
Cellestis Pty Ltd.
Cellestis Pty Ltd. BiotechnologyHealth Technology Cellestis Ltd. develops, manufactures and markets medical diagnostic products. It develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. Its product portfolio includes QuantiFERON-CMI kit, an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood, QuantiFERON-TB Gold, an in vitro diagnostic test for the detection of mycobacterium tuberculosis infection. The company was founded in 2000 and is headquartered in Chadstone, Australia. | 5 years |
Mark Blackburn | M | 67 | 9 years | |
Abe Tomas | M | - | 8 years | |
Suzanne Shepherd | F | - | - | |
Fiona Nash | F | - | - | |
Andrew Suckling | M | - | - | |
George Haramis | M | - | - | |
Elspeth Hunter | M | - | - | |
Simon Haidar | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
Australia | 39 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John G. Bennetts
- Personal Network